GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (LSE:CTEC) » Definitions » EV-to-Revenue

ConvaTec Group (LSE:CTEC) EV-to-Revenue : 3.70 (As of May. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is ConvaTec Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ConvaTec Group's enterprise value is £6,274 Mil. ConvaTec Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £1,695 Mil. Therefore, ConvaTec Group's EV-to-Revenue for today is 3.70.

The historical rank and industry rank for ConvaTec Group's EV-to-Revenue or its related term are showing as below:

LSE:CTEC' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.33   Med: 3.4   Max: 6.36
Current: 3.7

During the past 11 years, the highest EV-to-Revenue of ConvaTec Group was 6.36. The lowest was 2.33. And the median was 3.40.

LSE:CTEC's EV-to-Revenue is ranked worse than
54.55% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: 3.23 vs LSE:CTEC: 3.70

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-06), ConvaTec Group's stock price is £2.588. ConvaTec Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.83. Therefore, ConvaTec Group's PS Ratio for today is 3.13.


ConvaTec Group EV-to-Revenue Historical Data

The historical data trend for ConvaTec Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ConvaTec Group EV-to-Revenue Chart

ConvaTec Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.47 3.35 3.02 3.35 3.52

ConvaTec Group Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.02 - 3.35 - 3.52

Competitive Comparison of ConvaTec Group's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, ConvaTec Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ConvaTec Group's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ConvaTec Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ConvaTec Group's EV-to-Revenue falls into.



ConvaTec Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ConvaTec Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6273.595/1694.607
=3.70

ConvaTec Group's current Enterprise Value is £6,274 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ConvaTec Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £1,695 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ConvaTec Group  (LSE:CTEC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ConvaTec Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.588/0.826
=3.13

ConvaTec Group's share price for today is £2.588.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was £0.83.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ConvaTec Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ConvaTec Group (LSE:CTEC) Business Description

Traded in Other Exchanges
Address
23 Forbury Road, 3 Forbury Place, Reading, GBR, RG1 3JH
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and continence care are the largest divisions, accounting for 30% and 26% of total revenue, respectively. Ostomy contributes 25% of revenue and infusion sets 19%.

ConvaTec Group (LSE:CTEC) Headlines